OMS 405

Drug Profile

OMS 405

Alternative Names: OMS 403; OMS405

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Omeros Corporation
  • Developer New York State Psychiatric Institute; Omeros Corporation
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Opioid abuse; Smoking withdrawal
  • Preclinical Alcoholism

Most Recent Events

  • 16 Mar 2017 Preclinical development for Alcoholism is ongoing in the US
  • 16 Mar 2017 Omeros Corporation has patent protection for OMS 405 for addictive disorders in USA and ex-US countries
  • 02 Nov 2016 Pharmacodynamics data from a phase II trial in Opioid abuse released by Omeros
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top